A pilot study of the effects of crocin on high-density lipoprotein cholesterol uptake capacity in patients with metabolic syndrome: A randomized clinical trial.
Crocin
HDL functionality
HDL-C
metabolic syndrome
Journal
BioFactors (Oxford, England)
ISSN: 1872-8081
Titre abrégé: Biofactors
Pays: Netherlands
ID NLM: 8807441
Informations de publication
Date de publication:
Nov 2021
Nov 2021
Historique:
received:
13
06
2021
accepted:
11
08
2021
pubmed:
6
10
2021
medline:
25
2
2022
entrez:
5
10
2021
Statut:
ppublish
Résumé
A randomized clinical trial high-density lipoprotein (HDL) cholesterol uptake capacity (CUC) is reduced in patients with metabolic syndrome (MetS). We have assessed the effect of crocin supplementation on HDL CUC in patients with MetS. Forty-four subjects with MetS were randomly allocated to one of two groups: one group received placebo and the other group received crocin at a dose of 30 mg (two tablets of 15 mg per day) for 8 weeks. Serum biochemical parameters were measured using an AutoAnalyzer BT3000 (BioTechnica). The modified CUC method is a cell free, simple, and high-throughput assay that used to evaluate HDL CUC of serum samples. The decision tree analysis was undertaken using JMP Pro (SAS) version 13. The mean age of the crocin and placebo groups were 38.97 ± 13.33 and 43.46 ± 12.77 years, respectively. There was a significant increase in serum HDL CUC in the crocin group compared to that of the placebo group in patients with MetS (p-value< 0.05). The decision tree analysis showed that serum HDL functionality was more important variable than HDL-C level in predicting patients with hypertension at baseline (p-value < 0.05). Crocin administration (30 mg for a period of 8 weeks) was found to improve serum HDL CUC in patients with MetS. TRIAL REGISTRATION: IRCT2013080514279N1.
Substances chimiques
Cholesterol, HDL
0
Carotenoids
36-88-4
crocin
877GWI46C2
Types de publication
Journal Article
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
1032-1041Subventions
Organisme : Mashhad University of Medical Sciences
ID : 960443
Informations de copyright
© 2021 International Union of Biochemistry and Molecular Biology.
Références
McCracken E, Monaghan M, Sreenivasan S. Pathophysiology of the metabolic syndrome. Clin Dermatol. 2018;36(1):14-20.
O'Neill S, O'Driscol L. Metabolic syndrome: a closer look at the growing epidemic and its associated pathologies. Obes Rev. 2015;16:1-12.
Mabry RM, Reeves MM, Eakin EG, Owen N. Gender differences in prevalence of the metabolic syndrome in gulf cooperation council countries: a systematic review. Diabet Med. 2010;27:593-7.
Farmanfarma KK, Kaykhaei MA, Adineh HA, Mohammadi M, Dabiri S, Ansari-moghaddam A. Prevalence of metabolic syndrome in Iran: a meta-analysis of 69 studies. Diabetes Metab Syndr Clin Res Rev. 2019;13(1):792-9.
Abdullaev F, Espinosa-Aguirre J. Biomedical properties of saffron and its potential use in cancer therapy and chemoprevention trials. Cancer Detect Prev. 2004;28(6):426-32.
Nikbakht-Jam I, Khademi M, Nosrati M, Eslami S, Foroutan-Tanha M, Sahebkar A, et al. Effect of crocin extracted from saffron on pro-oxidant-anti-oxidant balance in subjects with metabolic syndrome: a randomized, placebo-controlled clinical trial. Eur J Integr Med. 2016;8(3):307-12.
Abe K, Saito H. Effects of saffron extract and its constituent crocin on learning behaviour and long-term potentiation. Phytother Res. 2000;14(3):149-52.
Nam KN, Park Y-M, Jung H-J, Lee JY, Min BD, Park S-U, et al. Anti-inflammatory effects of crocin and crocetin in rat brain microglial cells. Eur J Pharmacol. 2010;648(1-3):110-6.
Hosseinzadeh H, Karimi G, Niapoor M. Antidepressant effects of Crocus sativus stigma extracts and its constituents, crocin and safranal, in mice. J Med Plants. 2004;3(11):48-58.
Javandoost A, Afshari A, Nikbakht-Jam I, Khademi M, Eslami S, Nosrati M, et al. Effect of crocin, a carotenoid from saffron, on plasma cholesteryl ester transfer protein and lipid profile in subjects with metabolic syndrome: a double blind randomized clinical trial. ARYA Atheroscler. 2017;13(5):245-52.
Li J, Lei H-t, Cao L, Mi Y-N, Li S, Cao Y-X. Crocin alleviates coronary atherosclerosis via inhibiting lipid synthesis and inducing M2 macrophage polarization. Int Immunopharmacol. 2018;55:120-7.
Soran H, Hama S, Yadav R, Durrington PN. HDL functionality. Curr Opin Lipidol. 2012;23(4):353-66.
Holzer M, Wolf P, Inzinger M, Trieb M, Curcic S, Pasterk L, et al. Anti-psoriatic therapy recovers high-density lipoprotein composition and function. J Invest Dermatol. 2014;134(3):635-42.
Kelesidis T, Reddy ST, Huynh D, Meriwether D, Fogelman AM, Navab M, et al. Effects of lipid-probe interactions in biochemical fluorometric methods that assess HDL redox activity. Lipids Health Dis. 2012;11(1):87.
Kosmas CE, Martinez I, Sourlas A, Bouza KV, Campos FN, Torres V, et al. High-density lipoprotein (HDL) functionality and its relevance to atherosclerotic cardiovascular disease. Drugs Context. 2018;7:1-9.
Ganjali S, Dallinga-Thie GM, Simental-Mendía LE, Banach M, Pirro M, Sahebkar A. HDL functionality in type 1 diabetes. Atherosclerosis. 2017;267:99-109.
Benke K, Benke G. Artificial intelligence and big data in public health. Int J Environ Res Public Health. 2018;15(12):2796.
Saberi-Karimian M, Khorasanchi Z, Ghazizadeh H, Tayefi M, Saffar S, Ferns GA, et al. The potential value of data mining in clinical diagnostics, focusing on machine learning techniques. Crit Rev Clin Lab Sci. 2020;58:275-96. https://doi.org/10.1080/10408363.2020.1857681
Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials. Ann Intern Med. 2010;152(11):726-32.
Hadizadeh F, Mohajeri SA, Seifi M. Extraction and purification of crocin from saffron stigmas employing a simple and efficient crystallization method. Pak J Biol Sci. 2010;13(14):691-8.
Harada A, Toh R, Murakami K, Kiriyama M, Yoshikawa K, Miwa K, et al. Cholesterol uptake capacity: a new measure of HDL functionality for coronary risk assessment. J Appl Lab Med. 2017;2(2):186-200.
Aghasizadeh M, Samadi S, Sahebkar A, Miri-Moghaddam E, Esmaily H, Souktanloo M, et al. Serum HDL cholesterol uptake capacity in subjects from the MASHAD cohort study: its value in determining the risk of cardiovascular endpoints. J Clin Lab Anal. 2021;1:e23770.
Kermani T, Kazemi T, Molki S, Ilkhani K, Sharifzadeh G, Rajabi O. The efficacy of crocin of saffron (Crocus sativus L.) on the components of metabolic syndrome: a randomized controlled clinical trial. J Res Pharm Pract. 2017 Oct;6(4):228-32.
Ogita H, Liao JK. Endothelial function and oxidative stress. J Endothelial Cell Res. 2004;11(2):123-32. https://doi.org/10.1080/10623320490482664
Ozma A, Orăşan O, Sâmpelean D, Fodor A, Vlad C, Negrean V, et al. Endothelial dysfunction in metabolic syndrome. Rom J Intern Med. 2009;47(2):133-40.
Monette JS, Hutchins PM, Ronsein GE, Wimberger J, Irwin AD, Tang C, et al. Patients with coronary endothelial dysfunction have impaired cholesterol efflux capacity and reduced HDL particle concentration. Circ Res. 2016;119:83-90.
Didichenko SA, Navdaev AV, Cukier AM, Gille A, Schuetz P, Spycher MO, et al. Enhanced HDL functionality in small HDL species produced upon remodeling of HDL by reconstituted HDL, CSL112: effects on cholesterol efflux, anti-inflammatory and antioxidative activity. Circ Res. 2016;119:751-63.
Hansel B, Giral P, Nobecourt E, Chantepie S, Bruckert E, Chapman MJ, et al. Metabolic syndrome is associated with elevated oxidative stress and dysfunctional dense high-density lipoprotein particles displaying impaired antioxidative activity. J Clin Endocrinol Metab. 2004;89(10):4963-71. https://doi.org/10.1210/jc.2004-0305
Rohatgi A, Khera A, Berry JD, Givens EG, Ayers CR, Wedin KE, et al. HDL cholesterol efflux capacity and incident cardiovascular events. N Engl J Med. 2014;371(25):2383-93.
Ronsein GE, Heinecke JW. Time to ditch HDL-C as a measure of HDL function? Curr Opin Lipidol. 2017;28(5):414-8. https://doi.org/10.1097/MOL.0000000000000446
Saleheen D, Scott R, Javad S, Zhao W, Rodrigues A, Picataggi A, et al. Association of HDL cholesterol efflux capacity with incident coronary heart disease events: a prospective case-control study. Lancet Diabetes Endocrinol. 2015;3:507-13.
Khera AV, Cuchel M, de la Llera-Moya M, Rodrigues A, Burke MF, Jafri K, et al. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med. 2011;364(2):127-35. https://doi.org/10.1056/NEJMoa1001689
Shao B, Oda MN, Bergt C, Fu X, Green PS, Brot N, et al. Myeloperoxidase impairs ABCA1-dependent cholesterol efflux through methionine oxidation and site-specific tyrosine chlorination of apolipoprotein A-I. J Biol Chem. 2006;281:9001-4.
Rohatgi A. High-density lipoprotein function measurement in human studies: focus on cholesterol efflux capacity. Prog Cardiovasc Dis. 2015;58(1):32-40. https://doi.org/10.1016/j.pcad.2015.05.004
Chang CD, Wang CC, Jiang BC. Using data mining techniques for multi-diseases prediction modeling of hypertension and hyperlipidemia by common risk factors. Expert Syst Appl. 2011;38:5507-13.
Ture M, Kurta I, Kurumb AT, Ozdamar K. Comparing classification techniques for predicting essential hypertension. Expert Syst Appl. 2005;29:583-8.
Tayefi M, Esmaeili H, Karimian MS, Zadeh AA, Ebrahimi M, Safarian M, et al. The application of a decision tree to establish the parameters associated with hypertension. Comput Methods Programs Biomed. 2017;139:83-91.
Widlansky ME, Gokce N, Keaney JF, Vita JA. The clinical implications of endothelial dysfunction. J Am Coll Cardiol. 2003;42(7):1149-60.
Tran-Dinh A, Diallo D, Delbosc S, Varela-Perez LM, Dang QB, Lapergue B, et al. HDL and endothelial protection. Br J Pharmacol. 2013;169(3):493-511.